HER2 cancer vaccine - BioLife Science

Drug Profile

HER2 cancer vaccine - BioLife Science

Alternative Names: Her VAXX; HER-Vaxx; IMU-131; PEV 6A; PEV6

Latest Information Update: 01 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioLife Science; Pevion Biotech
  • Developer Imugene; Pevion Biotech
  • Class
  • Mechanism of Action ERBB 2 receptor antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Gastric cancer; Oesophageal cancer
  • No development reported Breast cancer

Most Recent Events

  • 31 Aug 2017 Phase-I/II clinical trials in Gastric cancer (Late-stage disease, Metastatic disease) in Taiwan, Hong Kong (IM)
  • 31 Aug 2017 Phase-I/II clinical trials in Oesophageal cancer (Late-stage disease, Metastatic disease) in Taiwan, Hong Kong (IM)
  • 01 Nov 2016 Phase-I/II clinical trials in Gastric cancer (Late-stage disease, Metastatic disease) in Thailand (IM) (NCT02795988)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top